541 related articles for article (PubMed ID: 33011853)
1. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
Holmøy T; Høglund RA; Illes Z; Myhr KM; Torkildsen Ø
J Neurol; 2021 Dec; 268(12):4522-4536. PubMed ID: 33011853
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
[TBL] [Abstract][Full Text] [Related]
3. [Treatment and new evidences in neuromyelitis optica spectrum disorder].
Illés Z
Ideggyogy Sz; 2021 Sep; 74(9-10):309-321. PubMed ID: 34657404
[TBL] [Abstract][Full Text] [Related]
4. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
Wallach AI; Tremblay M; Kister I
Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
Romeo AR
Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
[TBL] [Abstract][Full Text] [Related]
6. Adverse Events in NMOSD Therapy.
Giglhuber K; Berthele A
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456972
[TBL] [Abstract][Full Text] [Related]
7. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
[TBL] [Abstract][Full Text] [Related]
9. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E; Correale J
J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
[TBL] [Abstract][Full Text] [Related]
10. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
[TBL] [Abstract][Full Text] [Related]
11. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
Duchow A; Bellmann-Strobl J
Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
[TBL] [Abstract][Full Text] [Related]
12. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S;
Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418
[TBL] [Abstract][Full Text] [Related]
13. An update on biologic treatments for neuromyelitis optica spectrum disorder.
Kim W; Kim HJ
Expert Rev Clin Immunol; 2023 Jan; 19(1):111-121. PubMed ID: 36414430
[TBL] [Abstract][Full Text] [Related]
14. Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders.
Carreón Guarnizo E; Hernández Clares R; Castillo Triviño T; Meca Lallana V; Arocas Casañ V; Iniesta Martínez F; Olascoaga Urtaza J; Meca Lallana JE
Neurologia (Engl Ed); 2022 Apr; 37(3):178-183. PubMed ID: 35465911
[TBL] [Abstract][Full Text] [Related]
15. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.
Nakashima I; Nakahara J; Yasunaga H; Yamashita M; Nishijima N; Satomura A; Nio M; Fujihara K
Mult Scler Relat Disord; 2024 Apr; 84():105502. PubMed ID: 38401202
[TBL] [Abstract][Full Text] [Related]
16. [Neuromyelitis Optica Spectrum Disorder].
Misu T
Brain Nerve; 2021 May; 73(5):475-482. PubMed ID: 34006678
[TBL] [Abstract][Full Text] [Related]
17. What's new in neuromyelitis optica spectrum disorder treatment?
Chu YC; Huang TL
Taiwan J Ophthalmol; 2022; 12(3):249-263. PubMed ID: 36248092
[TBL] [Abstract][Full Text] [Related]
18. Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model.
Lazzaro C; Mazzanti NA; Rossi S; Parazzini F
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1185-1200. PubMed ID: 37795872
[TBL] [Abstract][Full Text] [Related]
19. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
Valencia-Sanchez C; Wingerchuk DM
BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
[TBL] [Abstract][Full Text] [Related]
20. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
Flanagan EP; Levy M; Katz E; Cimbora D; Drappa J; Mealy MA; She D; Cree BAC
Mult Scler Relat Disord; 2022 Jan; 57():103352. PubMed ID: 35158461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
